Quantum BioPharma Ltd. (QNTM)
NASDAQ: QNTM · Real-Time Price · USD
3.370
-0.030 (-0.88%)
Jul 16, 2026, 4:00 PM EDT - Market closed
Quantum BioPharma Employees
Quantum BioPharma had 17 employees as of December 31, 2022. The number of employees increased by 7 or 70.00% compared to the previous year.
Employees
17
Change (1Y)
7
Growth (1Y)
70.00%
Revenue / Employee
n/a
Profits / Employee
-$1,832,874
Market Cap
21.65M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2022 | 17 | 7 | 70.00% | 17 | 0 |
| Dec 31, 2021 | 10 | 1 | 11.11% | 10 | 0 |
| Dec 31, 2020 | 9 | -9 | -50.00% | 9 | 0 |
| Dec 31, 2019 | 18 | -1 | -5.26% | 17 | 1 |
| Sep 30, 2019 | 23 | 4 | 21.05% | 23 | 0 |
| Jun 30, 2019 | 19 | - | - | 19 | 0 |
| Dec 31, 2018 | 19 | - | - | 19 | 0 |
Related Stocks
| Company Name | Employees |
|---|---|
| Celularity | 115 |
| Evaxion | 46 |
| NextCure | 40 |
| Tevogen Bio Holdings | 18 |
| NewcelX | 12 |
| Cellectar Biosciences | 11 |
| VYNE Therapeutics | 10 |
| Akari Therapeutics, | 6 |
QNTM News
- 9 days ago - Quantum BioPharma Provides Corporate Update - GlobeNewsWire
- 20 days ago - NetworkNewsAudio Announces Audio Press Release (APR) the Advancement of First-in-Class Treatment for Multiple Sclerosis - GlobeNewsWire
- 21 days ago - Quantum BioPharma Ltd. (NASDAQ: QNTM) Advancing Innovative, First-in-Class, Patented MS Therapy - GlobeNewsWire
- 23 days ago - Quantum BioPharma Ltd. (NASDAQ: QNTM) Developing Patented, First-in-Class MS Treatment That Offers Different Approach - GlobeNewsWire
- 6 weeks ago - IBN Announces Latest Episode of The BioMedWire Podcast Featuring Anthony Durkacz, Executive Co-Chair of Quantum BioPharma Ltd. - GlobeNewsWire
- 6 weeks ago - Quantum BioPharma Engages Stocks.news For Investor Relations, Marketing Services And Lead Generation Campaigns - GlobeNewsWire
- 6 weeks ago - Quantum BioPharma Provides Corporate Update - GlobeNewsWire
- 2 months ago - Quantum BioPharma Reaches Key Midpoint Milestone in Groundbreaking Imaging Study with Massachusetts General Hospital - GlobeNewsWire